Clinical Trial

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This randomized phase II trial studies how well axitinib with or without anti-OX40 antibody PF-04518600 work in treating patients with kidney cancer that has spread to other parts of the body. Biological therapies, such as anti-OX40 antibody PF-04518600, use substances made from living organisms that may may stimulate the immune system in different ways and stop tumor cells from growing. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving axitinib with or without anti-OX40 antibody PF-04518600 may work better in treating patients with kidney cancer.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2017-03-22; most recent amendment 2026-05-29.
Status change: Recruiting → Active, Not Recruiting 2022-08-05
Status change: Not Yet Recruiting → Recruiting 2017-07-20
Trial Details
NCT Number NCT03092856
Lead Sponsor University of Southern California
Collaborators: National Cancer Institute (NCI)
Conditions Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Enrollment 62 participants
Start Date 2017-07-19
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-03